TICKERNERD
Menu
BTAIBTAIHealthcare · Drug Manufacturers - Specialty & Generic

BTAI Stock Forecast: BioXcel Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 4 Sept 2026
$0.07
−37.29% on the day

The 1 Wall Street analysts covering BioXcel Therapeutics, Inc. hold a median 12-month price target of $22 — +28954.1% from the last close.

Market cap
$1.7M
Ticker Nerd rank
—
Median analyst target
$22
Analysts covering
1
Revenue$182K+51.7% y/y
Operating income−$10.2M
Net income−$14.7M
Free cash flow−$6.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−59.1%
1M
−91.4%
YTD
−95.4%
1Y
−97.9%
From 52W high
−98.3%
From 52W low
0.0%
$0.07
$4.23
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

BTAI stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores BioXcel Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

We don’t hold a current model rank for this company.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

BTAI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BTAI, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$10.00$20.00$30.00$40.00Oct 25Jan 26Apr 26Jul 26BTAIHigh $38Median $22Low $5

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $5Median $22High $38

The green dot is the last close — the median target sits +28954.1% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
2 Apr 2026HC Wainwright & Co.MaintainsBuy$6.00 → $5.00
17 Mar 2026Rodman & RenshawInitiatesBuy—
5 Mar 2026HC Wainwright & Co.MaintainsBuy—
15 Sept 2025HC Wainwright & Co.ReiteratesBuy—
12 Sept 2025MizuhoMaintainsNeutral—
28 Aug 2025HC Wainwright & Co.ReiteratesBuy—
19 Aug 2025HC Wainwright & Co.ReiteratesBuy—
15 Aug 2025HC Wainwright & Co.MaintainsBuy—
15 July 2025LUCID CAPITAL MARKETSReiteratesBuy—
23 June 2025HC Wainwright & Co.MaintainsBuy—
19 Mar 2025Rodman & RenshawInitiatesBuy—
30 Jan 2025HC Wainwright & Co.MaintainsBuy—
7 Jan 2025B of A SecuritiesDowngradeUnderperform—
6 Jan 2025Canaccord GenuityMaintainsBuy—
21 Oct 2024HC Wainwright & Co.MaintainsBuy—
6 Sept 2024HC Wainwright & Co.ReiteratesBuy—
30 Aug 2024Canaccord GenuityMaintainsBuy—
9 Aug 2024UBSMaintainsNeutral—
8 Aug 2024HC Wainwright & Co.MaintainsBuy—
27 June 2024Canaccord GenuityMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BTAI appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

BTAI vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 4 Sept 2026, BioXcel Therapeutics, Inc. returned −97.9% against +20.0% for the S&P 500, dividends included.

BTAI vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Oct 25Jan 26Apr 26Jul 26BTAIS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

BTAI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

BioXcel Therapeutics, Inc. (BTAI) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.0×

Cheaper than 76% of US stocks

Price / sales
3.1×

Cheaper than 39% of US stocks

Price / book
−0.0×

Cheaper than 93% of US stocks

EV / EBITDA
−2.1×

Cheaper than 73% of US stocks

Growth & margins
Revenue growth (YoY)
51.7%

Higher than 86% of US stocks

Earnings growth (YoY)
51.7%

Higher than 75% of US stocks

Gross margin
87.9%

Higher than 95% of US stocks

Operating margin
−5600.5%

Higher than 3% of US stocks

Net margin
74.5%

Higher than 98% of US stocks

Returns & dividend
Return on equity
73.2%

Higher than 95% of US stocks

Return on assets
−102.4%

Higher than 2% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

BioXcel Therapeutics, Inc. (BTAI) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • BioXcel Therapeutics, Inc. has a market value of $1.7M and an enterprise value of $93.2M.

  • Revenue in the twelve months to 30 June 2026: $742K. The latest quarter grew 51.7% year on year.

  • Net income over the same four quarters: −$70.9M, a −9549.9% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$50.9M.

  • Shares outstanding: 31.3M.

  • Trailing P/E: −0.0×; forward P/E: −0.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • BioXcel Therapeutics, Inc. employs 29 people — $26K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 7 Oct 2026

Data provided by Twelve Data

Peers

BTAI vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
BTAIBioXcel Therapeutics, Inc.$1.7M
—
LLYEli Lilly & Co.*$1.1T
92
JNJJohnson & Johnson*$618.1B
85
ABBVAbbVie, Inc.*$481.3B
96
MRKMerck & Co., Inc.*$353.4B
82
UNHUnitedHealth Group, Inc.*$336.0B
74
TMOThermo Fisher Scientific, Inc.*$245.0B
82

* Nearest Healthcare names by size — few drug manufacturers - specialty & generic companies of this scale trade in the US universe.

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own BioXcel Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BTAI news & analysis

BioXcel Therapeutics Enters Into Asset Sale Agreement with Teva Pharmaceuticals

GlobeNewsWire · 28 Aug 2026negative

BioXcel Therapeutics announced it has entered into an asset sale agreement with Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries. BioXcel intends to complete a court-supervised sale with Teva as the "stalking horse" bidder in a 363 auction process, and has secured debtor-in-possession (DIP) financing to support ongoing operations.

Why it matters — The planned court-supervised asset sale, stalking-horse bid, and DIP financing signal that BioXcel is undergoing bankruptcy restructuring, which is significant for shareholders of the company.

Biopharma firm BioXcel Therapeutics files for bankruptcy in US

Reuters · 28 Aug 2026negative

AI-driven biopharma firm BioXcel Therapeutics filed for Chapter 11 bankruptcy protection in the U.S. on Thursday, according to Reuters.

Why it matters — A Chapter 11 bankruptcy filing is a significant corporate event that directly affects BioXcel Therapeutics and its shareholders.

BioXcel Therapeutics, Inc. (BTAI) Reports Q2 Loss, Misses Revenue Estimates

Zacks Investment Research · 14 Aug 2026neutral

BioXcel Therapeutics reported a second-quarter loss of $0.49 per share, narrower than the Zacks Consensus Estimate of a $0.51 loss and improved from a $2.45 per share loss a year ago, while revenue missed estimates.

Why it matters — The quarterly loss was smaller than both analyst expectations and the prior-year figure, though the revenue miss is a metric shareholders track closely.

FAQ

Frequently asked questions about BTAI stock

What is the BTAI stock price forecast for 2026-2027?

The 1 Wall Street analysts covering BioXcel Therapeutics, Inc. have a median 12-month price target of $22, with estimates ranging from $5 to $38. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BTAI stock a buy right now?

Of the 1 analysts covering BioXcel Therapeutics, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. None of this is personal advice — it does not consider your circumstances.

Will BTAI stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +28954.1% from the last close. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BTAI stock forecast for 2030?

No analyst covering BioXcel Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BTAI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $38 over the next 12 months.

How has BTAI stock performed over the past year?

BioXcel Therapeutics, Inc. returned -97.9% over the 12 months to 4 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does BioXcel Therapeutics, Inc. do?

BioXcel Therapeutics, Inc. is a biopharmaceutical company focused on developing medicines for neuroscience and immuno-oncology using artificial intelligence and data-driven drug discovery.

What is the latest news on BTAI?

The most recent item we track (GlobeNewsWire, 28 Aug 2026): "BioXcel Therapeutics Enters Into Asset Sale Agreement with Teva Pharmaceuticals". BioXcel Therapeutics announced it has entered into an asset sale agreement with Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries. BioXcel intends to complete a court-supervised sale with Teva as the "stalking horse" bidder in a 363 auction process, and has secured debtor-in-possession (DIP) financing to support ongoing operations.

Company

About BioXcel Therapeutics, Inc.

BioXcel Therapeutics, Inc. is a biopharmaceutical company focused on developing medicines for neuroscience and immuno-oncology using artificial intelligence and data-driven drug discovery. Its current portfolio includes IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults, as well as investigational programs built around BXCL501 and other proprietary candidates. The company’s neuroscience work addresses conditions such as agitation in dementia and major depressive disorder, while its immuno-oncology efforts are centered on oral immune-activating therapies for aggressive cancers through its subsidiary, OnkosXcel Therapeutics. Headquartered in New Haven, Connecticut, BioXcel Therapeutics operates as a commercial-stage specialty biotechnology company with a focus on advancing targeted treatment options in areas with significant unmet medical need.

CEO Dr. Vimal D. Mehta Ph.D. · 29 employees · United States · https://www.bioxceltherapeutics.com